Resistance to endocrine therapy is a significant therapeutic challenge in the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy have been shown to improve progression free survival, overall response rate and clinical benefit rate in women with HR+ HER2-metastatic breast cancer compared with endocrine therapy alone. This review examines the clinical evidence to support the use of CDK4/6 inhibitors in first and second line settings. Practical guidance is provided for the use of CDK4/6 inhibitors, including tolerability data, monitoring requirements and management of key toxicities for each of the available agents.
INTRODUCTION
Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer is the most common subtype of breast cancer accounting for more than 70% of cases. 1 It is well established that endocrine therapy improves outcomes for patients with early and metastatic HR+, HER2-breast cancer. Endocrine therapies block estrogen-driven tumor growth through a number of different mechanisms providing an array of opportunities for resistance to develop. De novo or acquired resistance to endocrine therapy results in treatment failure, which limits survival and prevents cure in patients with metastatic disease. With advances in understanding of tumor biology, these mechanisms may potentially be overcome by specific inhibitors against molecules upregulated or mutated in resistant cells.
Cyclin-dependent kinase (CDK)4/6, a downstream target of estrogen receptor (ER) signaling that regulates cell entry into the cell cycle, represents such a mechanism that may be activated by alternative routes in this setting. Cyclin-CDK complexes regulate proliferation in breast cancer cells through phosphorylation and inactivation of the retinoblastoma tumor suppressor protein (Rb). 2 Hyperphosphoryla-inhibition appears to have an independent antiangiogenic role in tumor therapy. 2 Three CDK4/6 inhibitors, ribociclib, palbociclib and abemaciclib, are either approved or in late stage clinical trials. All three drugs in combination with endocrine therapy have been shown to improve progression free survival (PFS) in HR+ HER2-metastatic breast cancer compared with endocrine therapy alone in the first and second line settings, leading to a significant shift in patterns of care. [3] [4] [5] [6] [7] [8] [9] [10] [11] Although clinical data is very similar for the three agents, molecular and functional profiling suggest there may be some subtle differences in activity. 12 Ribociclib has been listed for reimbursement with the Pharmaceutical Benefits Scheme (PBS) in Australia since July 1, 2018. Palbociclib is Therapeutic Goods Administration (TGA) approved for first and second line use in combination with endocrine therapy. 13, 14 Abemaciclib is not currently approved for use in Australia. All three CDK4/6 inhibitors are also currently being evaluated in clinical trials for high risk early breast cancer patients (NCT02831530, NCT02513394, NCT03078751).
We conducted a search of the literature for Phase II to IV clinical trials using CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib We review the clinical evidence to support the use of CDK4/6 inhibitors, assess tolerability and provide practical guidance for the use of CDK4/6 inhibitors in clinical practice.
CLINICAL TRIAL DATA: EFFICACY

First line in postmenopausal women
The efficacy data for CDK4/6 inhibitors in combination with a nonsteroidal aromatase inhibitor (NSAI) for first line treatment of HR+ HER2-metastatic breast cancer in postmenopausal women is derived from three phase III double-blind randomized controlled trials (MONARCH-3 6 , PALOMA-2 15 and MONALEESA-2 8 ) and one phase II study (PALOMA-1 5 ) ( Table 1 ). In addition, the MONALEESA-3 study compared ribociclib in combination with the selective estrogen receptor degrader (SERD) fulvestrant to fulvestrant plus placebo and included patients who had received one prior line of therapy as well as treatment-naïve patients. 16 First line CDK4/6 inhibitors in combination with a NSAI improved PFS compared to a NSAI plus placebo (HR between 0.49 and 0.58 in postmenopausal women with HR+, HER2-metastatic breast cancer). 6, 8, 15 Considering the combination arms, median PFS in the PALOMA-2 study for palbociclib with letrozole was 24.8 months (95% CI 22.1 to not estimable (NE)) 15 and in MONALEESA-2, for ribociclib plus letrozole median PFS was 25.3 months (95% CI 23.0 to 30.3). 17 In the MONARCH-3 study, PFS for abemaciclib and letrozole was not reached in the abemaciclib combination arm after a median follow-up of 17.8 months. 6 The median PFS for a NSAI alone in the three studies ranged from 10.2 to 16 months in keeping with previous studies of NSAIs. 18 Median PFS was not reached in the sub-group of patients receiving first line ribociclib plus fulvestrant in MONALEESA-3; in the fulvestrant alone arm median PFS was 18.3 months (hazard ratio (HR) 0.58; 95% CI, 0.42 to 0.80) (Figure 1 ). 10 Overall response rates (ORR) for CDK4/6 inhibitors in combination with a NSAI, ranged between 42.1% and 48.2%, compared to 28.7% to 34.7% for an NSAI with placebo. The clinical benefit rate (CBR) for patients receiving both a CDK4/6 inhibitor and a NSAI ranged from 78% to 84.9% compared to 58% to 72.8% in those receiving the NSAI plus placebo. The PALOMA-2 study reported 22.5 months median duration of response for the combination arm compared to 16.8 months for the control arm. In the MONARCH-3 study, median duration of response was not reached for the active arm and was 14.1 months in the control arm. After a median follow-up period of 15.3 months in the MONALEESA-2 study, median duration of response was not reached in either arm. 19 Overall survival (OS) in the PALOMA-3 study showed a positive trend in the hazard ratio favoring palbociclib, similar in absolute terms to the improvement in median PFS, although this trend did not reach statistical significance. 20 
Second or later lines in postmenopausal women
Each of the three CDK4/6 inhibitors, in combination with the SERD fulvestrant, also improved PFS in second or later lines of therapy.
The phase III studies MONALEESA-3, MONARCH-2 and PALOMA-3 demonstrated a median PFS of 20.5 months (first and second line combined), 16.4 months and 9.5 months in the combination arms compared with the fulvestrant monotherapy arms of 12.8, 9.3 and 4.6 months respectively, with similar HR to those seen in the first line studies. 3, 10, 11 In the sub-group of patients receiving second line ribociclib plus fulvestrant in the MONALEESA-3 study, median PFS was 14.6 months compared to 9.1 months in the fulvestrant alone arm (HR 0.57; 95% CI, 0.43 to 0.74). 10, 16 
Premenopausal women
Other subgroups
Comparable efficacy has also been demonstrated in the sub-group with de novo advanced breast cancer in the MONALEESA-2 study.
The median PFS was not reached in the ribociclib plus letrozole arm compared with 16.4 months with letrozole (HR 0.45; 95% CI 0.27 to 0.75). 25 In addition, ribociclib plus a NSAI also had clinical activity in patients with high burden of disease, and was associated with a lower rate of treatment discontinuation in patients with three or more metastatic sites compared to placebo (45% vs. 60%). 26 There were no sub-groups that did not appear to benefit from the addition of CDK4/6 inhibitors to a NSAI across all trials. The most prominent benefit differential appeared to be between Asian and Caucasian patients with Asian patients obtaining a larger relative benefit in PFS in all studies but one (MONARCH-3: HR 0.30; 95% CI 0.17 to 0.52; PALOMA-2: HR 0.48, 95% CI 0.27 to 0.87; MONALEESA-2: HR 0.39, 95% CI 0.17 to 0.91; PALOMA-1: HR not reported). 5, 6, 8, 15 The other trend is that patients with a tumor expressing only estrogen or progesterone receptors rather than both, appear to derive more benefit from the addition of a CDK4/6 inhibitor (MONALEESA-2: HR 0.396, 95% CI 0.20 to 0.65). 8 This raises the question as to whether studies of grade, metastatic site, Ki67 or luminal A relative to luminal B tumors would also show differentials.
Monotherapy
While the majority of trials in HR+, HER2-breast cancer have evaluated CDK4/6 inhibitors in combination with endocrine therapy, there are some data for CDK4/6 inhibitors demonstrating single agent activity in the second line or later setting (Table 1 ). In the phase II TREnd study comparing palbociclib plus an AI to palbociclib alone, the primary endpoint of CBR was 60% (95% CI, 48% to 73%) in the combination arm compared to 54% (95% CI, 42% to 67%) with palbociclib alone. 9 Single agent abemaciclib demonstrated clinical activity in the refractory setting. MONARCH-1 was a phase II single arm study of abemaciclib at a higher dose of 200 mg twice daily and was associated with an overall response rate of 19.7% (95% CI, 13.3% to 27.5%). 27 
Quality of life
Health related Quality of Life questionnaires (HRQoL) were included in the MONALEESA-2 and PALOMA-3 studies. [28] [29] [30] In the first line setting, the addition of ribociclib to letrozole maintained quality of life (HR 0.89; 95% CI 0.67 to 1.18). 30 Clinically meaningful reduction in pain was also observed as early as week 8 and maintained for at least 15 cycles. 31 In the second or later lines, the addition of palbociclib to fulvestrant significantly improved overall global HRQoL scores relative to endocrine therapy alone (66.1; 95% CI 64.5 to 67.7 vs. 63.0 95% CI 60.6 to 65.3; P = 0.0313). 28 In addition, palbociclib plus fulvestrant significantly improved EuroQoL-5D scores. 29 
BIOMARKERS FOR RESPONSE
A number of biomarker hypotheses have been explored in attempts to identify patients that will obtain the most benefit from CDK4/6 inhibition in combination with standard anti-estrogen therapy. This is partly driven by the cost effectiveness, the efficacy of anti-estrogens alone in some patients and the potential toxicity of this class of compounds. ER, Rb, p16, cyclin D1 (CCND1) and Ki67. 32, 33 Only ER showed predictive value for response to CDK4/6 inhibitors. Of note the majority of studies were carried out on the primary tumor.
With regard to links between efficacy and toxicity, in PALOMA-3 no correlation with efficacy was seen for either degree of neutropenia, nor for dose adjustments made on account of neutropenia. 34 No studies to date have confirmed this lack of association for other toxicities or other agents.
Turning to the monitoring of potential sub-clones during therapy using blood-based DNA analysis, initial assessment of 52 patients from the PALOMA-3 study showed that PFS was significantly longer with fulvestrant and palbociclib in patients with relatively larger reductions in circulating PiK3CA ctDNA over the first 15 days of therapy suggesting that relative clonal proportions may influence eventual outcomes. 35 Table 2 provides an overview of NCI-CTCAE grade 3 or 4 adverse events of special interest reported in the first line phase III studies of CDK4/6 inhibitors. Dose reductions due to adverse events were reported in 36% to 51% of patients receiving a CDK4/6 inhibitor compared with between 0% and 19% for those receiving placebo. 6,8,15
TOLERABILITY
Hematological adverse events
In first line phase III clinical trials of a CDK4/6 inhibitor, 66.4%, 59.3% and 21.1% of patients receiving palbociclib, ribociclib and abemaciclib experienced grade 3 or 4 neutropenia and 24.8%, 21.0% and 7.6% experienced grade 3 or 4 leukopenia, respectively (Table 2) As with palbociclib, the phase III MONARCH-2 study that included patients receiving first or second line abemaciclib with fulvestrant showed similar rates of grade 3 or 4 hematological toxicity to the first line MONARCH-3 study. 11
QTc prolongation
In the MONALEESA-2 study, 3.3% (n = 11) of patients receiving ribociclib experienced prolongation of QTc interval to more than 480 ms. 8 Nine patients (2.7%) had an increase of more than 60 ms from baseline. Changes in QTc interval occurred mostly in the first 4 weeks of treatment. Most patients with QT prolongation continued treatment with 600 mg ribociclib without interruption. Patients with high risk of QTc prolongation were excluded from the trial, and concomitant medications with this propensity were carefully screened for. In a single reported case of sudden death, a patient who had taken a prohibited concomitant medication with a known risk for QT prolongation (methadone) developed prolonged QTcF interval and hypokalemia during cycle 2. 8 Palbociclib and abemaciclib on the other hand have not been shown to prolong the QTc interval. 37 No other cardiac abnormalities have been reported for the CDK4/6 inhibitors.
Other adverse events
Grade 3 or 4 increases in alanine and aspartate transaminase levels have been observed with CDK4/6 inhibitors ( Table 2) . 6, 8, 15 These are generally asymptomatic and reversible with dose adjustment (Table 4) . 13, 14 In the first line phase III studies, grade 3 or 4 diarrhea was more commonly reported in patients receiving abemaciclib (9.5%) compared with palbociclib (1.4%) or ribociclib (1.2%). 6, 8, 15 In the single agent abemaciclib study, which was administered at a higher dose (MONARCH 1), diarrhea rather than neutropenia was the dose limiting toxicity. A study with neoadjuvant abemaciclib using aggressive prophylactic loperamide therapy is currently underway.
In MONARCH 2 and MONARCH 3, a higher incidence of venous thromboembolic events was observed in the abemaciclib arm. 6, 11 In MONARCH 3, the majority of patients who experienced these events did not discontinue abemaciclib. 6 Rates of grade 3 or 4 fatigue were similar for all CDK4/6 inhibitors (approximately 2%) across the same studies. 6, 8, 15 However, fatigue of any grade was reported between 36.5% and 40.1% of patients receiving a CDK4/6 inhibitor compared with 27.5% to 31.7% of those receiving an AI alone.
NSAIs have been described previously to cause both male and female pattern hair loss and this appears to be exacerbated by the addition of a CDK inhibitor. 38 There were no reports of grade 3 or 4 alopecia across the first line phase III studies, however alopecia of any grade in the experimental arm was reported in 26.6% of patients in the MONARCH-3 study, 32.9% in PALOMA-2 and 33.2% in the MONALEESA-2 study, compared with10.6%, 15.8% and 15.5% in the placebo group respectively. 6,8,15 (Table 3 ).
PATIENT MANAGEMENT
CDK4/6 inhibitor dose adjustments for neutropenia require close monitoring in the first few cycles particularly, until a stable dose is established (Table 3 and Table 4 ). Neutrophil recovery tends to be rapid on cessation of therapy. Palbociclib and ribociclib are dosed for 21 days followed by 7 days' rest during each 28-day cycle to allow for recovery of neutrophils. Abemaciclib, with its lower propensity for neutropenia is dosed continuously. 40 Patients receiving abemaciclib should be provided with loperamide and instructed to commence it at the first sign of loose stools. The dose can be interrupted or reduced if diarrhea fails to settle, escalates to grade 3, or there is persistent grade 2 diarrhea for more than 7 days (Table 4 ).
CDK4/6 inhibitors are metabolized by CYP3A, therefore drugs that inhibit or induce CYP3A including several antifungals and antivirals or non-prescription drugs such as cannabis, should be avoided in combination with CDK4/6 inhibitors. 41, 42 If necessary to use the treatments concomitantly, the dose of the CDK4/6 inhibitor may be adjusted and neutrophil count monitored closely. Grapefruit juice and pomegranate juice should also be avoided.
For patients scheduled for surgery, it is suggested that CDK4/6 inhibitor therapy is interrupted for 7 days prior to surgery and for 3 weeks after surgery to avoid neutropenia during wound healing and recovery time. 41 For radiotherapy, there is preclinical data suggesting both potential prevention of radiation-induced toxicity, presumptively by induction of cellular quiescence in normal proliferating tissues, 43 as well as synergy of anticancer effect through direct reactivation of Rb suppression 44 and inhibition of DNA repair by CDK4/6 inhibitors. 45 However, controlled clinical studies are required before considering combining radiation and CDK4/6 treatment routinely, and cessation of CDK4/6 inhibition during radiotherapy is currently recommended.
DISCUSSION
Comparable efficacy has been demonstrated for the CDK4/6 inhibitors whether given first or second line, and regardless of the choice of backbone endocrine therapy. PFS, ORR and CBR data for CDK4/6 inhibitors show consistent improvement compared to endocrine therapy alone.
While the PFS data is extremely encouraging, data for OS remains immature. A key reason for the lack of mature OS data is the significant prolongation of PFS by CDK4/6 inhibitors compared to endocrine therapy alone such that there are insufficient deaths within the prespecified follow-up periods of the phase III trials to accurately report OS. PFS as a surrogate for OS has therefore played a critical role in the approval of these agents.
While CDK4/6 inhibitors are associated with an increased risk of hematological adverse events, these events are predictable and manageable. Furthermore, a meta-analysis of phase II and III clinical trials showed that the rate of febrile neutropenia is not increased compared to endocrine therapy. 46 Monitoring of patients for potential toxicity is required prior to and through the early stages of treatment.
The more commonly reported adverse events can be managed by dose modification.
Limitations of this review include that it was not conducted as a registered systematic review or meta-analysis. There are limited numbers of studies included in this review.
CONCLUSIONS
CDK4/6 inhibitors in combination with endocrine therapy represent a significant advance in the treatment of patients with HR+, HER2-metastatic breast cancer. Timely, consistent access to CDK4/6 inhibitors is therefore critical to improve clinical outcomes for patients in Australia.
While current evidence shows a clear role for CDK4/6 inhibitors with endocrine therapy for the first or second line treatment of HR+, HER2-metastatic breast cancer, there is scope for better understanding of their broader role within the clinic. In our accompanying review, we explore the use of CDK4/6 inhibitors in different regimens, combinations and dosing schedules. We consider their role for treating patients with CNS metastases or HR+, HER2+ metastatic breast cancer. Additionally, we look at treatment options for patients with progression of disease after a CDK4/6 inhibitor, including mechanisms of resistance and the role of biomarkers. 
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